Drug Profile
Basiliximab - Novartis
Alternative Names: CHI 621; Chimeric RFT5; chRFT5; SDZ CHI 621; SimulectLatest Information Update: 03 Dec 2021
Price :
$50
*
At a glance
- Originator Novartis
- Developer Cerimon Pharmaceuticals; Novartis
- Class Monoclonal antibodies
- Mechanism of Action Immunosuppressants; Interleukin 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Renal transplant rejection; Transplant rejection
- Discontinued Ulcerative colitis; Uveitis
Most Recent Events
- 22 Sep 2014 Launched prior to this date for Renal transplant rejection in Argentina, Mexico, Canada, Venezuela, Chile, Indonesia, China, Malaysia, Philippines, Singapore, Hong Kong, South Africa, Australia, New Zealand, Belgium, Denmark, Ireland, Finland, France, Germany, Greece, Hungary, Poland, Portugal, Sweden, Czech Republic, Norway, Turkey, Russia & Ukraine (IV)
- 22 Sep 2014 Launched prior to this date for Transplant rejection in Brazil & Thailand (IV)
- 01 Mar 2013 Novartis completes its phase II IDEALE trial for Renal transplant rejection in France (NCT01596062)